Thailand Medical Cannabis Export to Germany & the EU: Inside Solar Farm’s GACP Supply

UPDATED: JULY 18, 2026

Thai cannabis export to Germany is no longer a theoretical route: it is a working supply chain, and Solar Farm operates inside it. We are a GACP-certified indoor cannabis farm in Thailand supplying wholesale medical flower to licensed buyers in Germany and the wider EU, one of a small number of Thai farms holding both Thai GACP and EU-GACP compliance, with a licensed German buyer under partnership since 2025.

This guide is written for the people who make that trade happen: German and EU importers, wholesalers and procurement managers qualifying a second-origin supplier, and Thai operators studying the export path. It covers the numbers German buyers plan around, the full post-2024 German licence chain, the EU-GMP release route, the Thai side of the equation, and a qualification checklist you can forward to your compliance team.

This guide is general information for licensed businesses, not legal advice. Licence decisions sit with BfArM, the competent Länder authorities and their Thai counterparts.

Germany in 2026: The Numbers Importers Are Planning Around

Germany is widely cited as the world’s largest medical cannabis import market, and 2025 was the year it broke away: 201.1 tonnes imported, pharmacy sales crossing EUR 1 billion. The first quarter of 2026 added 50.5 tonnes, up a third on the year, though down from an exceptional Q4, putting the trailing twelve months above 218 tonnes. Published forecasts for full-year 2026 run to roughly 250 tonnes.

Two structural facts matter more to a procurement desk than the headline growth. First, concentration: Canada supplied 53% of Q1 2026 volume (26.8 tonnes), with Portugal second at 10.3 tonnes and Denmark third at 3.3. That single-origin dependence is why German importers are actively qualifying second-origin suppliers: DEMECAN, among others, has publicly announced diversifying its international supplier network. The 2025 origin tables already show the newcomers arriving:

Second, the ceiling: Germany imposes no country-of-origin quota, but it does operate an aggregate annual estimate under the international narcotics conventions. In 2025 the original 122-tonne estimate was exhausted by September, BfArM briefly paused new import approvals, and the estimate was raised to 192.5 tonnes, with actual imports finishing at 201.1. The ceiling is origin-neutral and adjustable, but it is real, and it rewards importers whose supply plans and permits are filed early in the year rather than negotiated in Q4.

Thai Cannabis Export to Germany: The Import Licence Chain, Step by Step

Germany reformed its cannabis law in April 2024, and much of what circulates online still describes the old regime. The current chain for a medical cannabis importer in Germany bringing in third-country flower has four elements.

1. The §4 MedCanG licence: permission to handle medical cannabis

Since April 1, 2024, medical cannabis sits under the Medizinal-Cannabisgesetz (MedCanG), not the narcotics act: cannabis was removed from the BtMG annexes. Anyone cultivating, manufacturing, trading, importing or exporting medical cannabis in Germany needs a licence under §4 MedCanG, issued by BfArM’s Federal Opium Agency (Bundesopiumstelle). This replaced the former §3 BtMG narcotics licence; if a guide or supplier still cites BtMG as the current basis, it is out of date. For a Thai supplier, this is also the first thing to verify about a prospective buyer: no §4 MedCanG licence, no deal.

2. The §72 AMG import licence, which covers wholesale of your own imports

Importing medicinal products from outside the EU requires an import licence under §72 AMG, issued not by BfArM but by the competent state authority. A detail worth knowing: under §52a Abs. 6 AMG, the §72 licence includes wholesale authorisation for the products it covers, so an importer can wholesale its own third-country imports without a separate §52a AMG wholesale licence. A separate §52a licence is only needed to trade product the company did not import itself, which is why many distributors hold both. The practical consequence for both sides of the deal: confirm early that the licence’s product scope, not just its existence, covers the flower you plan to trade.

3. Per-shipment import permits under §12 MedCanG

The standing licences are not enough on their own. Each individual consignment needs its own import permit from BfArM under §12 MedCanG, with the established foreign-trade procedures continuing to apply via §14 MedCanG. This is the step most overview articles skip, and it is where supply planning meets paperwork: permits are tied to specific shipments, quantities and suppliers, so the exporting farm’s documentation has to match the permit application exactly. Treat the permit as part of the order cycle, not an afterthought: batch numbers, quantities and certificates on the Thai side must mirror the German application, and mismatches are the most common avoidable delay in the whole chain.

4. Release against the European Pharmacopoeia monograph

Since July 1, 2024, the binding quality standard for cannabis flower is the European Pharmacopoeia monograph “Cannabis flower” (Ph. Eur. 3028); it replaced the national DAB “Cannabisblüten” monograph, which was deleted from the pharmacopoeia in 2025. Flower is tested and released against it by a Qualified Person at an EU-GMP-certified site: identity, cannabinoid assay against the declared THC/CBD content, foreign matter, loss on drying, microbiological quality, aflatoxin B1 and heavy metals, with risk-based pesticide testing. Every requirement on that list is a line item a supplier’s batch documentation must anticipate, which is exactly how our per-batch third-party certificates of analysis are structured, with in-house HPLC testing in commissioning to add a first-line check. The releasing Qualified Person is the last gate before German wholesale; a farm that structures its documentation around the monograph makes that release routine instead of a negotiation.

In sequence, then: standing licences first (§4 MedCanG, §72 AMG), an EU-GMP release partner second, and per-shipment §12 MedCanG permits matched to each consignment, with the supplier’s export dossier feeding every stage.

The EU-GMP Gateway: How GACP Flower Becomes Pharmacy Product

A question we hear from buyers on both sides: does the Thai farm need EU-GMP certification? No, and understanding why unlocks the whole third-country model. Cultivation runs under GACP (Good Agricultural and Collection Practice); manufacturing steps run under EU-GMP. Third-country flower (Canadian, Colombian, South African, Thai) routinely ships to an EU-GMP-certified processor, with Portugal the established hub (and the #2 supplier to Germany in Q1 2026 at 10.3 tonnes), where it is tested, processed where needed, packaged and released by a Qualified Person before entering German wholesale. The farm supplies audited GACP cultivation plus complete batch documentation; the EU-GMP site releases against the pharmacopoeia. This division of labour is the standard GACP cannabis export route into the EU.

Two currents are reshaping the gateway, and buyers should factor in both. First, regulators are tightening what they call “GMP washing”: a German state authority has taken the position that drying is a manufacturing-critical step that should happen where the plant is grown, and that decontamination must be validated, a stance that pushes importers to expect post-harvest steps to be done properly, and documented, at origin rather than patched up in Europe. That scrutiny favours farms that dry, cure and document on site under GACP SOPs, as we do: you can inspect the process in our room-by-room compliance walkthrough. Second, the Portugal route itself is congested: export-permit lead times there have stretched from around 30 days to 70 or more, and other processing hubs are competing for the role. A supplier with clean documentation and flexible routing is worth more than one locked to a single corridor.

One statistical footnote that matters for how Thailand’s role is read: industry analysts point out that German import statistics in practice record the country a batch is dispatched from, not where the plant was cultivated. Because third-country flower is routinely grown under GACP and then tested, released and packaged in Portugal before shipping onward, much of it is counted as Portuguese-origin. They therefore note that official country-of-origin figures likely understate true third-country participation: Thailand’s cannabis export to Germany, reported at 0.1 tonnes, is likely a floor rather than a full measure.

Why Dual Thai GACP + EU-GACP Matters

Thailand’s Department of Thai Traditional and Alternative Medicine issues Thai GACP certification, and as of February 13, 2026 only 217 farms held it, against more than 11,800 licensed operators. But a DTAM certificate alone is not how European buyers qualify a farm: EU practice is that GACP compliance is evidenced by audit, and importers or their EU-GMP partners audit primary producers directly. That is why we maintain both: EU-GACP compliance on top of Thai GACP certification, with the audit trail: SOPs, batch records, training logs, calibration records, kept inspection-ready year round. If you want the plain-language version of what the standard demands, start with what GACP certification actually requires.

A Certificate of Analysis on Every Batch

Every batch leaving our facility carries a certificate of analysis: cannabinoid potency (certified by an independent laboratory), microbiological quality, heavy metals and pesticide screening: the same categories the Ph. Eur. monograph puts in front of the releasing Qualified Person. Batch and cultivation records trace each lot to its room, cycle and inputs. For an importer, that means the documentation your §12 MedCanG permit application and your EU-GMP partner’s release both depend on exists before you ask for it.

The Thai Side in Two Minutes

Thailand has been medical-only since mid-2025, and the April 2026 ministerial regulations tightened flower licensing around premises, storage, personnel and DTAM-trained staff, while unlicensed bud export became a customs offence carrying penalties up to 10 years. Export by licensed operators is the channel Thai policy deliberately preserves: flower export runs on an operator-level DTAM licence under the controlled-herbs regime, with shipment-level matching driven by the destination country’s per-consignment permits. One date every buyer should have in the diary: licences issued under the pre-2026 framework expire on December 31, 2026, with full re-qualification required. We track every instrument, date and pending bill, including the draft Cannabis and Hemp Act, in our Thailand Cannabis and Hemp Act 2026 tracker, updated within 48 hours of major developments.

Importer Requirements Checklist: Qualifying a Thai Supply Partner

Forward this to your compliance team. Part A is what the German importer holds; Part B is what to demand from any Thai farm before a term sheet.

Solar Farm supplies every Part B item as a standard export dossier: that is the point of building the farm around the audit rather than bolting the audit onto the farm.

Regulatory Risk Watch: What Could Change

Candour is part of qualification, so here is the risk side. In Germany, the proposed MedCanG amendment (in-person prescriptions, a mail-order ban) cleared Cabinet in October 2025 but remains stalled in the Bundestag health committee: no plenary vote was held before the July 2026 summer recess, the Bundesrat rejected the mail-order penalty provisions, and telehealth prescribing and pharmacy mail-order remain fully legal today. If a softened version eventually passes, the platform-driven segment of demand could slow; pharmacy-dispensed flower under physician prescription, the segment certified importers serve, remains the structural core of a 200-tonne-plus market. Separately, the annual import estimate can bind late in the year, as 2025 showed. The practical hedge on both: suppliers offering flexible MOQs and mixed grades (trimmed flower, processing-grade un-trimmed, popcorn), so import permits and budgets can be re-planned without re-qualifying a new farm. On the Thai side, the December 2026 re-qualification cliff is the risk to diligence now; our tracker follows it week by week.

Proof, Not Promises: Inside the Farm

The claims above are inspectable. Our indoor facility in Pathum Thani, 22 flowering rooms across 5,800 m², runs air-locked entry, PPE protocols, IPM pest control, calibrated environmental monitoring and documented drying and curing, each with its own published SOP, linked from the compliance walkthrough. Genetics run through our exclusive indoor strains at 24–30% THC, certified per batch, and ship as trimmed flower, un-trimmed processing grade or popcorn, with white-label and OEM supply available for buyers building their own brands. Current market terms are on our Thailand wholesale price guide, and the broader domestic framework is covered in our medical cannabis Thailand guide and wholesale overview for licensed buyers.

How Licensed Buyers Start

1. Enquire with your licence details. We work with licensed businesses only and verify counterparties first.
2. Receive the export dossier. Certifications, audit summary, sample COAs, batch-record structure and stability data where available: everything Part B of the checklist asks for.
3. Audit us. Remote document audit or an on-site visit under our visitor-management SOP; your EU-GMP partner is welcome in the room.
4. Contract and permit alignment. Quantities, grades and timelines matched to your §12 MedCanG permit applications and Thai export authorisation.
5. Ship via your EU-GMP release route. Batch documentation travels with the consignment; your Qualified Person releases against Ph. Eur. 3028.

Ready to qualify a second origin? Contact our export team for the dossier.

Frequently Asked Questions

Can you import medical cannabis from Thailand to Germany?

Yes. Germany imposes no country-of-origin quota: imports are lawful from any country cultivating under state control per the international conventions, provided the flower meets pharmacopoeia standards. The importer holds a §4 MedCanG licence, a §72 AMG import licence and per-shipment §12 MedCanG permits; the Thai farm supplies GACP-cultivated flower with full batch documentation, released through an EU-GMP-certified site. Thailand licenses medical cannabis export through DTAM, and Thai flower already appears in Germany’s import statistics, flagged for strong increase.

What licences does a German importer need for Thai cannabis flower?

Three layers: a §4 MedCanG licence from BfArM’s Federal Opium Agency (this replaced the pre-2024 §3 BtMG narcotics licence); a §72 AMG import licence from the competent state authority, which also covers wholesale of the company’s own imports under §52a Abs. 6 AMG; and an individual import permit under §12 MedCanG for every consignment. The per-shipment permit is the step to plan around, because it is tied to a named supplier, quantity and consignment.

Does a Thai farm need EU-GMP certification to supply Germany?

No. Cultivation runs under GACP; EU-GMP applies to manufacturing and release, which happens at an EU-GMP-certified site in Europe; Portugal is the established hub. What the farm must supply is audited GACP compliance and complete batch documentation. Note that regulators are tightening scrutiny of post-harvest steps: drying and curing are increasingly expected to happen, documented, at origin, which favours farms that dry on site under GACP SOPs.

Is it still legal to export cannabis from Thailand after the 2025 recriminalization?

Yes. Thailand’s 2025 tightening, often called a recriminalization, ended recreational sales, not medical exports. Licensed operators export under DTAM’s controlled-herbs regime, tightened further by the April 2026 ministerial regulations, while unlicensed export is now a customs offence carrying penalties up to 10 years. The buyer-relevant caveat is the December 31, 2026 licence sunset: verify any supplier’s re-qualification status before contracting into 2027.

What testing must Thai flower pass for German pharmacies?

Release is against the European Pharmacopoeia “Cannabis flower” monograph (Ph. Eur. 3028), mandatory since July 2024, which replaced the German DAB monograph: identity, cannabinoid assay against declared content, foreign matter, loss on drying, microbiological quality, aflatoxin B1 and heavy metals, plus risk-based pesticide screening. The supplier’s per-batch COA should anticipate every category, so the Qualified Person’s release is routine rather than a negotiation.

Is there a limit on how much medical cannabis Germany can import?

There is no per-country quota, but Germany files an aggregate annual estimate under the international narcotics conventions. In 2025 the initial 122-tonne estimate was exhausted by September, approvals briefly paused, and the estimate was raised to 192.5 tonnes; actual imports reached 201.1 tonnes. The ceiling adjusts, but it rewards importers who file supply plans and permits early in the year.